Men1 mouse studies claim pre-clinical proof-of-concept for gene replacement therapy in pituitary NETs.

Clinical and pre-clinical studies of neuroendocrine tumours (NETs) in multiple endocrine neoplasia type 1 (MEN1), and evaluation of MEN1 gene replacement therapy for MEN1-associated NETs.
-Gerard Walls, Paul Newey, et al.
Endocrine Abstracts (2013) 31 YEP1.1 | DOI:10.1530/endoabs.31.YEP1.1

MEN1 gene replacement therapy reduces proliferation rates in a mouse model of pituitary adenomas

MEN1 gene replacement therapy reduces proliferation rates in a mouse model of pituitary adenomas
-G Walls, M Lemos, et al.
Journal of Cancer Research, OnlineFirst August 21, 2012; doi: 10.1158/0008-5472.CAN-12-1821

• "In this study, we conducted a preclinical evaluation of MEN1 gene therapy in pituitary tumors of Men1+/- mice, using a recombinant non-replicating adenoviral serotype 5 vector..."
  
• "Menin expression was higher in the Men1.rAd5-treated mice when compared to other groups. Daily proliferation rates assessed by BrdU incorporation were reduced significantly in Men1.rAd5-injected tumors relative to control treated tumors."
  
• "Our findings establish that MEN1 gene replacement therapy can generate menin expression in pituitary tumors, and significantly reduce tumor cell proliferation."